BIBP 3226 trifluoroacetate: Precision NPY Y1 & NPFF Antagonist for Cardiovascular and Neurobiology Research

Executive Summary: BIBP 3226 trifluoroacetate is a non-peptide antagonist for neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptors, exhibiting high affinity in both rat and human systems (APExBIO). The compound blocks NPFF-induced inhibition of cAMP signaling in cell models and reverses NPFF-mediated hypothermic and anti-opioid effects in vivo (Fan et al., 2024). Recent studies confirm that the NPY/Y1R pathway is a therapeutic target in epicardial adipose tissue-driven cardiac arrhythmias. BIBP 3226 trifluoroacetate enables precise dissection of these pathways, supporting research in neurobiology, anxiety, analgesia, and cardiovascular regulation. The product's purity (>98%) and robust quality control facilitate reproducible results in advanced experimental designs (internal guidance).

Biological Rationale

Neuropeptide Y (NPY) and neuropeptide FF (NPFF) are critical modulators in neural and cardiovascular systems. The NPY/Y1 receptor pathway regulates anxiety, stress adaptation, and cardiovascular tone (Fan et al., 2024). NPFF receptors modulate pain processing and opioid responses. The adipose-neural axis couples adipocyte-derived leptin, sympathetic neurons, and NPY/Y1R signaling, contributing to arrhythmogenesis in epicardial adipose tissue (EAT)-related cardiac arrhythmias. Increased EAT thickness and elevated NPY levels are biomarkers for atrial fibrillation. Pharmacological antagonism of Y1R and NPFF provides mechanistic leverage for dissecting these pathways in disease models (Decoding the NPY/NPFF Axis – this article extends that foundation by providing new experimental benchmarks in cardiac models).

Mechanism of Action of BIBP 3226 trifluoroacetate

BIBP 3226 trifluoroacetate (CAS: 1068148-47-9) acts as a competitive antagonist at NPY Y1 and NPFF receptors. In competitive binding assays, it demonstrates a Ki of 1.1 nM for rat NPY Y1, 79 nM for human NPFF2, and 108 nM for rat NPFF receptors (APExBIO). This high affinity enables effective pathway blockade at nanomolar concentrations. In cell-based models, BIBP 3226 antagonizes NPFF-induced inhibition of forskolin-stimulated cAMP production. By blocking NPY/Y1R, it inhibits downstream activation of the Na+/Ca2+ exchanger (NCX) and CaMKII, two effectors implicated in arrhythmogenic signaling (Fan et al., 2024). In rodent models, BIBP 3226 reverses NPFF-dependent hypothermic and anti-opioid effects. The compound’s non-peptide structure confers metabolic stability and broad compatibility with in vitro, ex vivo, and in vivo systems.

Evidence & Benchmarks

• BIBP 3226 trifluoroacetate blocks Y1R-mediated arrhythmogenic effects in stem cell-based coculture models of the adipose-neural axis (Fan et al., 2024).
• In competitive binding assays, BIBP 3226 exhibits a Ki of 1.1 nM for rat NPY Y1 receptors, confirming high specificity and potency (APExBIO).
• The antagonist prevents NPFF-induced inhibition of forskolin-stimulated cAMP production in cell culture models, validating its utility in signal transduction research (Fan et al., 2024).
• BIBP 3226 blocks NPFF-dependent hypothermic and anti-opioid effects in rodent in vivo assays, demonstrating translational relevance (APExBIO internal).
• In studies of EAT-driven arrhythmia, Y1R blockade (including with BIBP 3226) reduces arrhythmic phenotypes, supporting therapeutic exploration (Fan et al., 2024).

Applications, Limits & Misconceptions

BIBP 3226 trifluoroacetate is widely used for:

• Dissecting the NPY/NPFF system in models of anxiety, analgesia, and cardiovascular regulation.
• Validating the role of Y1R signaling in epicardial adipose tissue-related cardiac arrhythmias (Decoding the Adipose-Neural Axis – this article provides updated benchmarks in advanced coculture models).
• Screening the functional effects of NPY/NPFF antagonism in neurobiology and translational models.
• Pathway dissection in cAMP signaling, leveraging its antagonism of NPFF-induced cAMP inhibition.

However, several boundaries must be recognized:

Common Pitfalls or Misconceptions

• BIBP 3226 trifluoroacetate does not antagonize all NPY receptor subtypes—its principal activity is at Y1 and NPFF receptors.
• The compound is not a peptide and does not mimic endogenous peptides in metabolism or pharmacokinetics.
• It is not intended for diagnostic or therapeutic use in humans or animals (APExBIO).
• Long-term storage of solutions is not recommended; stability is optimal with prompt use after dissolution.
• Some cell types or disease states with altered receptor expression may require empirical titration for optimal results.

This article clarifies recent advances over previous overviews by benchmarking BIBP 3226 in the context of the latest adipose-neural axis and arrhythmia findings.

Workflow Integration & Parameters

BIBP 3226 trifluoroacetate is supplied as an off-white solid (C29H32F3N5O5; MW 587.59). For experimental use:

• Solubility: ≥78 mg/mL in DMSO, ≥73.2 mg/mL in ethanol, ≥12.13 mg/mL in water (with ultrasonic assistance).
• Storage: -20°C (dry, for solid). Solutions should be prepared fresh and used promptly.
• Quality Control: Purity >98% (HPLC, MS, NMR, COA supplied by APExBIO).
• Recommended concentrations: nanomolar to micromolar range, depending on assay sensitivity and receptor density.
• Compatible with in vitro, ex vivo, and in vivo models (not for diagnostic or clinical use).

Integrating BIBP 3226 in advanced coculture or pathway studies supports robust, reproducible results. For scenario-driven protocols and safety best practices, see our detailed workflow guide, which this article expands by including new arrhythmia model data.

Conclusion & Outlook

BIBP 3226 trifluoroacetate from APExBIO is a validated, high-specificity non-peptide antagonist for NPY Y1 and NPFF receptors. Its selectivity, metabolic stability, and data-backed performance make it a gold-standard reagent for exploring the NPY/NPFF axis in neurological and cardiovascular research. Recent mechanistic studies underscore the therapeutic potential of targeting Y1R in EAT-driven arrhythmias. Future work will likely extend the utility of BIBP 3226 to additional disease models and precision pathway mapping.